Αρχειοθήκη ιστολογίου

Σάββατο 9 Σεπτεμβρίου 2017

Osimertinib for resistant lung cancer improves PFS vs SoC, with 54% reduction of progression/death, plus control of… https://t.co/vdo0LzSqgj

Osimertinib for resistant lung cancer improves PFS vs SoC, with 54% reduction of progression/death, plus control of… https://t.co/vdo0LzSqgj

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://twitter.com/ecancer/status/906407386847604737
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,

Αναζήτηση αυτού του ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader